Literature DB >> 1685016

A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.

A Tarakhovsky1, T Zaichuk, V Prassolov, Z A Butenko.   

Abstract

Medium conditioned by mouse peritoneal macrophages, activated by muramyl dipeptide (MDP), was used as a possible source of p185neu-specific ligand. MDP-activated macrophage-conditioned medium (MDP-CM) was shown to induce p185neu down-regulation in NEU-expressing NIH3T3 cells in a dose-dependent and temperature-sensitive manner. To exclude the possibility of an indirect action of proteins/metabolites present in MDP-CM on p185neu turnover, a ligand-trapping approach was used. Secreted NEU protein possessing only the extracellular domain but lacking transmembrane and protein kinase domains was expressed in HeLa cells and then purified from conditioned medium, using affinity chromatography on WGA-Sepharose. Co-incubation of the truncated, soluble NEU protein preparation with MDP-CM abolished MDP-CM-induced p185neu down-regulation and reduced self-phosphorylation. It is concluded that a putative p185neu-specific ligand is produced by macrophages activated by MDP. Using MDP-CM, the presence of a 25 kDa polypeptide distinct from EGF, PDGF, FGF, IGF, TGF-alpha and TGF-beta and TNF-alpha, could be demonstrated by decorating a Western blot with soluble NEU and anti-NEU antibodies. Thus, a 25 kDa (non-reduced) p185neu ligand has been described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685016

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.

Authors:  U Srinivas; E Tagliabue; M Campiglio; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

Review 2.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 4.  Epidermal growth factor-related peptides in the pathogenesis of human breast cancer.

Authors:  N Normanno; F Ciardiello; R Brandt; D S Salomon
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

5.  Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin].

Authors:  A Staebler; C Sommers; S C Mueller; S Byers; E W Thompson; R Lupu
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

Authors:  D Karunagaran; E Tzahar; R R Beerli; X Chen; D Graus-Porta; B J Ratzkin; R Seger; N E Hynes; Y Yarden
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

7.  Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells.

Authors:  E Tagliabue; E Ardini; R Pellegrini; M Campiglio; R Bufalino; M Jeschke; B Groner; M I Colnaghi; S Ménard
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.

Authors:  E Peles; R Ben-Levy; E Tzahar; N Liu; D Wen; Y Yarden
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.